Background:Staphylococcus aureus may produce superantigens that can non-specifically activate CD4+ cells to potentially target the myelin basic protein.
Objective: This study examined the association between individuals with multiple sclerosis (MS) and colonization with S. aureus harbouring superantigens.
Methods: Nasal swabs were collected from non-MS subjects and patients with MS who had not experienced a relapse in the past six months (MS stable group) and who had suffered a relapse within 30 days of study recruitment (MS exacerbation group). S. aureus was isolated from the anterior nares of participants following standard procedures and staphylococcal superantigen genes (sea, seb, and tsst-1) were detected using standard laboratory PCR techniques.
Results: The study enrolled 204 patients, 80 in the non-MS and MS stable groups and 44 patients in the MS exacerbation group. Overall, 27.0% of patients were colonized with S. aureus with no significant differences identified between study groups. Amongst individuals colonized with S. aureus, the prevalence of sea was significantly greater in the MS exacerbation versus non-MS study group (p < 0.05; odds ratio 7.9; 95% confidence interval 1.2–49.5).
Conclusions: The ability to rapidly screen patients for the presence of S. aureus producing sea may serve as a useful marker of a potential MS exacerbation.
ConfavreuxCAimardGDevicM. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patient?Brain1980; 103: 281–300.
2.
OzenciVKouwenhovenMLinkH. Cytokines in multiple sclerosis: methodological aspects and pathogenic implication?Mult Scler2002; 8: 396–404.
3.
ConlonPOksenbergJRZhangJSteinmanL. The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous syste?Neurobiol Dis1999; 6: 149–166.
4.
WucherpfennigKW. Mechanisms for the induction of autoimmunity by infectious agent?J. Clin Invest2001; 108: 1097–1104.
5.
LibbeyJEMcCoyLLFujinamiRS. Molecular mimicry in multiple sclerosi?Int Rev Neurobiol2007; 79: 127–147.
6.
WucherpfennigKWStromingerJL. Molecular mimicry in T-cell mediated autoimmunity-viral peptides activate human T-cell clones specific for myelin basic-protei?Cell1995; 80: 695–705.
7.
OlsonJKCroxfordJLMillerSD. Innate and adaptive immune requirements for induction of autoimmune demyelinating disease by molecular mimicr?Mol Immunol2004; 40: 1103–1108.
8.
TorresBAKominskySPerrinGQHobeikaACJohnsonHM. Superantigens: the good, the bad, and the ugl?Exp Biol Med2001; 226: 164–176.
9.
BrockeSGaurAPiercyCGautamAGijbelsKFathmanCG. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantige?Nature1993; 365: 642–644.
StinissenPVandevverCRausJZhangJ. Superantigen reactivity of gamma delta T cell clones isolated from patients with multiple sclerosis and control?Cell Immunol1995; 166: 227–235.
12.
KrakauerT. Immune response to staphylococcal superantigen?Immunol Res1999; 20: 163–173.
13.
HuLUmedaAKondoSAmakoK. Typing of Staphylococcus aureus colonising human nasal carriers by pulsed-field gel electrophoresi?J Med Microbiol1995; 42: 127–132.
14.
LeedomJMKennedyRPLepperMHJacksonGGDowlingHF. Observations of the staphylococcal nasal carrier stat?Ann NY Acad Sci1965; 128: 381–403.
15.
PaulMOLamikanraAAderibigbeDA. Nasal carriers of coagulase-positive staphylococci in a Nigerian hospital communit?Trans R Soc Trop Med Hyg1982; 76: 319–323.
PoserCMPatyDWScheinbergLMcDonaldWIDavisFAEbersGC. New diagnostic criteria for multiple sclerosis: guidelines for research protocol?Ann Neurol1983; 13(3): 227–231.
18.
VollmerT. The natural history of relapses in multiple sclerosi?J Neurol Sci2007; 256(Suppl. 1): S5–S13.
19.
Kloos WE and Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 6th ed. Washington, D.C: American Society for Microbiology; 1995. pp. 282–298.
20.
MehrotraMWangGJohnsonWM. Multiplex PCR for detection of genes for Staphylococcus aureus enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1 and methicillin resistanc?J Clin Microbiol2000; 38: 1032–1035.
RitzHLKirklandJJBondGGWarnerEKPettyGP. Association of high levels of serum antibody to staphylococcal toxic shock antigen with nasal carriage of toxic shock antigen-producing strains of Staphylococcus aureus?Infect Immun1984; 43: 954–958.
23.
VerkaikNJDe VogelCPBoelensHAGrumannDHoogenboezemTVinkC. Anti-staphylococcal humoral immune response in persistent nasal carriers and non-carriers of Staphylococcal aureus?J Infect Dis2009; 199: 625–632.
24.
SandriAMDalarosaMGRuschel de AlcantaraLda Silva EliasLZavasckiAP. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRS?Infect Control Hosp Epidemiol2006; 27: 185–187.
25.
EllisMWGriffithMEDooleyDPMcleanJCJorgensenJHPattersonJE. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled tria?Antimicrob Agents Chemother2007; 51: 3591–3598.
26.
StegemanCATervaertJWde JongPEKallenbergCG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapse of Wegener’s granulomatosi?N Engl J Med1996; 335: 16–20.
27.
SchafferACLeeJC. Staphylococcal vaccines and immunotherapie?Infect Dis Clin North Am2009; 23: 153–171.
28.
NikodemovaMJLeeJFabryZDuncanID. Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cor?J Neuroimmunol2010; 219(1–2): 33–37.
29.
ZabadRKMetzLMTodorukTRZhangYMitchellJRYeungM. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot stud?Mult Scler2007; 13(4): 517–526.
